GUIDE TO ROTH CONVERSIONS
'We are the bridge between your Accountant and Financial Advisor: We do what they don't'— David Hyden
MCKINNEY, TX, UNITED STATES, April 26, 2025 / EINPresswire.com / -- For individuals contemplating whether to convert their traditional IRAs, 401(k)s, and other tax-qualified retirement plans to a Roth IRA, Retirement Tax Consultants is now offering a comprehensive Roth Conversion Analysis.
Making the right decision about Roth conversion can save retirees hundreds of thousands of dollars over time—but only if it's based on accurate, personalized analysis. While some local advisors may be equipped to perform these calculations, the reality is that Roth analysis requires deep expertise in tax strategy, mathematics, and retirement income planning.
Retirement Tax Consultants fills this gap by offering clients a professional-grade report set designed to evaluate all aspects of Roth conversion. These reports answer the most critical questions a retirement account owner must ask:
________________________________________
Our Roth Conversion Report includes a side-by-side analysis comparing the long-term costs of converting versus not converting:
1. THE COST OF CONVERSION
• Tax cost of a conventional single-year conversion
• Tax cost of a structured (multi-year) conversion
• Tax cost of a strategically optimized single-year conversion using proprietary tax strategies
• Fees and risks associated with an optimized conversion
• D1RV (Day-One Roth Value) for each approach
• Enhancement options available, with analysis of appropriateness and cost
2. THE COST OF NOT CONVERTING
• Lifetime income taxes (voluntary and RMDs)
• Increased Medicare premiums
• IRMAA surcharges (Income-Related Monthly Adjustment Amount)
• Investment fees and commissions on the embedded tax liability
________________________________________
'With our tools, expertise, and software, we can show clients the true cost and benefit of a Roth conversion and help them decide if the Roth conversion makes sense financially. This is not just a financial guess—it's a fact-based analysis that empowers clients to make the best decision for their retirement future,' said David Hyden, Founder of Retirement Tax Consultants.
'For those clients that decide to convert to Roth we can also show them how to reduce the taxes by a minimum of 35% using various strategies that are legal yet largely unknown by most advisers.'
________________________________________
To schedule your Roth Analysis, contact Retirement Tax Consultants today:
📞 Call: 469-342-8889
📩 Email: [email protected]
🌐 Visit: https://retirementtaxconsultants.com
David B. Hyden
Retirement Tax Consultants
email us here
Visit us on social media:
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
7 hours ago
- Miami Herald
Trying to find a job in this economy? South Florida experts have advice for you
With layoffs across industries, finding work can be a challenge. But it's not impossible. In July, at Miami Beach's ColorComm Conference for professionals of color, job recruiter Nicole Reboe and human resources professional Kim Seymour shared seven tips for professionals looking for new jobs or looking to elevate within their companies. Here are their tips for job seekers navigating a difficult market: Reboe said job seekers need to present themselves as a professional in real life and on social platforms like LinkedIn. 'How am I seeing you show up?' she asked. 'How am I seeing you talk about your career' Reboe is aware of the challenges that job seekers have with finding work right now. She says it's important for them to stay motivated and not give up. 'It is the market,' she said. ' Don't internalize it. Stay the course.' When people are looking for new jobs, Seymour said it's important for them to tap into their network of contacts. 'If I'm in my company job right now, or if I've left for whatever reason, I am immediately pivoting to who I know,' she said. Just as networking can help job seekers find jobs faster, Seymour said it's also important to focus on those who have been longtime supporters of you and your work. 'Who's bringing your name into a room?' she asked. 'The only way that happens is if you have the right relationships and if the right people are saying the right things.' Seymour said job seekers should use numbers to describe the value they have brought to their work. 'Quantify what you've done,' she said. Seymour emphasized that job seekers research potential employers to make sure they fit with the culture. 'I would personally not join a company that is not aligned with what I can tolerate,' she said. 'Be picky.' In addition to presenting yourself well, Reboe said it's important to understand what colleagues and collaborators think about working with you. 'When it comes to work that I do, I'm speaking to people who work with you,' she said. 'What do they say about you? What are your strengths?'
Business Wire
8 hours ago
- Business Wire
NetApp Hosts First Quarter of Fiscal Year 2026 Financial Results Webcast
SAN JOSE, Calif.--(BUSINESS WIRE)--After market close on August 27, 2025, NetApp (NASDAQ: NTAP) will announce financial results for the first quarter of fiscal year 2026, which ended July 25, 2025. NetApp executive management will host a conference call Webcast at 2:30 p.m. Pacific Time to discuss these results and provide their perspective on market dynamics. How to Participate The live Webcast call can be accessed at Please allow at least 15 minutes prior to the start of the Webcast to log in. An audio replay Webcast will also be available after 4:30 p.m. Pacific Time. NetApp Future Targeted Release Dates Q2 FY 2026 results target date: November 25, 2025 Q3 FY 2026 results target date: February 26, 2026 Q4 FY 2026 results target date: May 28, 2026 Q1 FY 2027 results target date: September 2, 2026 About NetApp NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data, operational and workload services to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry's best data management. As the only enterprise-grade storage service natively embedded in the world's biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our operational and workload services provide continuous optimization of performance and efficiency for infrastructure and workloads through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at or follow us on X, LinkedIn, Facebook, and Instagram. NETAPP, the NETAPP logo, and the marks listed at are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
NBC News
8 hours ago
- NBC News
Trump gives drugmakers 60 days to slash prescription drug prices
President Donald Trump sent letters to more than a dozen major drugmakers Thursday demanding that they lower the cost of prescription drugs in the U.S. within 60 days. In the letters — which Trump published on his social media platform Truth Social — the drugmakers were told to offer the 'full portfolio' of their existing medications to Medicaid patients at the same prices paid abroad, also known as the 'most favored nation' rule. He also told drugmakers to 'guarantee' that patients on Medicare, Medicaid and private insurance get the same lower prices that are paid abroad for all newly approved drugs 'both upon launch and moving forward.' He also demanded that drugmakers return any additional revenues earned abroad to U.S. taxpayers, and create a 'direct to consumer' option for certain medications that would also be offered at lower prices. 'Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government, and American patients,' Trump wrote in the letters. 'But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices.' It's unclear, experts say, whether Trump has the authority to force drugmakers to lower the cost of their prescription drugs without the help of Congress. What's more, any attempt to do so is likely to be met with fierce pushback from the drug industry. 'It may take more than a tough letter from the President to motivate the pharmaceutical industry to drop their prices,' said Tricia Neuman, executive director of the program on Medicare policy at KFF, a nonpartisan health policy research group. 'The voluntary approach hasn't worked so far to drive down drug prices,' she added. 'Drug prices tend to go down when compelled by law or in response to competition.' Trump has repeatedly complained — during both terms — that people in the U.S. pay far more for prescription drugs than people in other countries. Indeed, prescription drug prices in the United States are notoriously high — up to 10 times more than in other nations of similar size and wealth, according to the Rand Corp., a public policy think tank. More than 3 in 4 adults in the U.S. say the cost of medications is unaffordable, according to a poll from KFF. In May, Trump signed an executive order instructing federal health officials to renew an effort to implement the 'most favored nation' rule — a strategy he pursued unsuccessfully during his first term. The 17 letters were sent Thursday to major drugmakers such as Eli Lilly, GSK, Pfizer, Merck, Johnson & Johnson, Amgen, Novo Nordisk and Novartis. NBC News has reached out to all 17 companies for comment. A spokesperson for Novo Nordisk said the company 'remains focused on improving patient access and affordability, and we will continue to work to find solutions that help people access the medication they need.' A spokesperson for Johnson & Johnson said the company was still reviewing the letter, and referred NBC News to the pharmaceutical industry's top lobbying group, PhRMA, for comment. PhRMA did not immediately respond to a request for comment. The Trump administration does have another tool at its disposal to lower the cost of prescription drugs: Medicare drug pricing negotiations. Signed into law by President Joe Biden through the Inflation Reduction Act, the provision allows Medicare to negotiate prices on the costliest medications. The first round of negotiations is estimated to save Medicare $6 billion in 2026, when the prices are expected to go into effect.
